Mycoplasma Testing Market by Products, Application, Technology, End User - Global Forecast to 2019

The global mycoplasma testing market is expected to reach $613.49 million by 2019 from $340.29 million in 2014, growing at a CAGR of 12.51% between 2014 and 2019. The mycoplasma testing product segments included in this report are instruments, kits & reagents, and services. The kits & reagents segment is further divided on the basis of type into stains, elimination kits, PCR assays, nucleic acid detection kits, standards & controls and other kits & reagents. The technology segments included are microbial culture techniques, DNA staining, PCR, ELISA, direct assay, indirect assay and enzymatic methods. On the basis of applications, the report is segmented into cell line testing, virus testing, end of production cells testing and other applications. The cell line testing applications had the largest share of the mycoplasma testing market in 2014. The cell line testing application is expected to be one of the fastest growing applications between 2014 and 2019.

The geographic segments included in this report are North America, Europe, Asia and Rest of the World (RoW). The geographic analysis reveals that North America accounted for the largest share in the global mycoplasma testing market in 2014. Asia regional segment, on the other hand, is expected to register a faster growth from 2014 to 2019, due to the increasing demand for mycoplasma testing and drug discovery and research from this region.

The key driver for this market is increased research funding by government. Furthermore, growing biotechnology and pharmaceutical companies to increase R&D activities and innovations in life science research and will aid the growth of the global mycoplasma testing market.

A combination of bottom-up and top-down approaches were used to calculate the market sizes and growth rates of the global mycoplasma testing market and its sub-segments. Secondary information was used to identify the overall revenues, geographic reach, and product portfolios of the market players. Estimates of their mycoplasma testing product segment revenues were validated through primary interviews. Primary interviews with key opinion leaders were also used to determine percentage shares of each sub segment and the relative differences in the growth rates.

The report provides qualitative insights about key market shares, growth rates, and market drivers for all important sub segments. It maps the market sizes and growth rates of each sub segment and identifies the segments poised for rapid growth in each of the geographic segments. The report also includes company profiles of the market leaders. These company profiles include financial performances, product portfolios, and market developments for each company. The report also provides a competitive landscape of the mycoplasma testing market. The competitive landscape covers the growth strategies adopted by the industry players over the last four years. It also includes analysis of industry developments like expansions, agreements and partnerships, mergers and acquisitions and new product launches.

Reasons to Buy the Report:
The report will enable both established firms and new entrants to gauge the pulse of the market and help them make important strategic growth decisions.

The report provides insights on the following:
‧ Product Development: Product portfolios of the top players in the mycoplasma testing market.
‧ Competitive Assessment: In-depth assessment of the market shares, strategies, geographic and business segments, and product portfolios of the leading players in the mycoplasma testing market.
‧ Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the market for various mycoplasma testing products across geographies.

TABLE OF CONTENTS

1 INTRODUCTION 17
1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKET DEFINITION 17
1.3 MARKET SCOPE 18
1.3.1 MARKETS COVERED 18
1.3.2 YEARS CONSIDERED FOR THE STUDY 19
1.4 CURRENCY 19
1.5 STAKEHOLDERS 19
2 RESEARCH METHODOLOGY 20
2.1 MARKET SIZE ESTIMATION 21
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 24
2.3 MARKET SHARE ESTIMATION 25
2.3.1 KEY DATA FROM SECONDARY SOURCES 25
2.3.2 KEY DATA FROM PRIMARY SOURCES 26
2.3.3 ASSUMPTIONS 26
3 EXECUTIVE SUMMARY 27
4 PREMIUM INSIGHTS 33
4.1 MYCOPLASMA TESTING MARKET TO GROW AT A RATE OF 12.51% IN THE FORECAST PERIOD 33
4.2 LIFE CYCLE ANALYSIS, BY REGION 35
5 MARKET OVERVIEW 36
5.1 INTRODUCTION 37
5.2 MARKET SEGMENTATION 37
5.2.1 MYCOPLASMA TESTING MARKET, BY PRODUCT 37
5.2.2 MYCOPLASMA TESTING MARKET, BY TECHNOLOGY 37
5.2.3 MYCOPLASMA TESTING MARKET, BY APPLICATION 38
5.2.4 MYCOPLASMA TESTING MARKET, BY END USER 38
5.3 MARKET DYNAMICS 39
5.3.1 DRIVERS 39
5.3.1.1 Rapid growth in the pharmaceutical and biotechnology industries 39
5.3.1.2 Strong trend of R&D investments in life sciences 40
5.3.1.3 Increasing government support for pharmaceutical and biotechnology industries 41
?
5.3.2 RESTRAINTS 42
5.3.2.1 High degree of consolidation acts as an entry barrier for new entrants 42
5.3.2.2 Stringent regulatory frameworks and time-consuming approval processes 42
5.3.3 OPPORTUNITIES 43
5.3.3.1 Increasing pharmaceutical outsourcing 43
6 INDUSTRY INSIGHTS 45
6.1 INTRODUCTION 45
6.2 PORTER’S FIVE FORCES ANALYSIS 45
6.2.1 THREAT OF NEW ENTRANTS 45
6.2.2 THREAT OF SUBSTITUTES 46
6.2.3 BARGAINING POWER OF BUYERS 46
6.2.4 BARGAINING POWER OF SUPPLIERS 46
6.2.5 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS 46
6.3 STRATEGIC BENCHMARKING 47
6.3.1 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS 47
6.4 SUPPLY CHAIN ANALYSIS 48
6.4.1 KEY INFLUENCERS 49
7 MYCOPLASMA TESTING MARKET, BY PRODUCT 50
7.1 INTRODUCTION 51
7.2 KITS & REAGENTS 52
7.2.1 PCR ASSAYS 55
7.2.2 NUCLEIC ACID DETECTION KITS 56
7.2.3 ELIMINATION KITS& REAGENTS 58
7.2.4 STAINS 59
7.2.5 STANDARDS & CONTROLS 61
7.2.6 OTHER KITS & REAGENTS 62
7.3 INSTRUMENTS 64
7.4 SERVICES 65
8 MYCOPLASMA TESTING MARKET, BY TECHNOLOGY 67
8.1 INTRODUCTION 68
8.2 PCR 69
8.3 ELISA 71
8.4 DIRECT ASSAY 72
8.5 INDIRECT ASSAY 73
8.6 DNA STAINING 74
8.7 MICROBIAL CULTURE TECHNIQUES 76
8.8 ENZYMATIC METHODS 77
?
9 MYCOPLASMA TESTING MARKET, BY APPLICATION 79
9.1 INTRODUCTION 80
9.2 CELL LINE TESTING 81
9.3 VIRUS TESTING 83
9.4 END OF PRODUCTION CELLS TESTING 84
9.5 OTHER APPLICATIONS 86
10 MYCOPLASMA TESTING MARKET, BY END USER 87
10.1 INTRODUCTION 88
10.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 89
10.3 CONTRACT RESEARCH ORGANIZATIONS 92
10.4 ACADEMIC RESEARCH INSTITUTES 93
10.5 CELL BANKS 95
10.6 OTHER END USERS 97
11 GEOGRAPHIC ANALYSIS 99
11.1 INTRODUCTION 100
11.2 NORTH AMERICA 102
11.2.1 U.S. 109
11.2.2 CANADA 114
11.3 EUROPE 119
11.4 ASIA 124
11.5 REST OF THE WORLD (ROW) 131
12 COMPETITIVE LANDSCAPE 137
12.1 INTRODUCTION 137
12.2 MARKET SHARE ANALYSIS, MYCOPLASMA TESTING MARKET 138
12.3 COMPETITIVE SITUATION AND TRENDS 140
12.3.1 AGREEMENTS, COLLABORATIONS AND PARTNERSHIPS 140
12.3.2 EXPANSIONS 141
12.3.3 ACQUISITIONS 142
12.3.4 NEW PRODUCT AND SERVICE LAUNCHES 143
12.3.5 OTHER STRATEGIES 144
13 COMPANY PROFILES 145
13.1 INTRODUCTION 145
13.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 146
13.2.1 BUSINESS OVERVIEW 146
13.2.2 PRODUCTS & SERVICES 147
13.2.3 RECENT DEVELOPMENTS 147
13.2.4 MNM VIEW 148
13.2.4.1 Financial analysis 148
13.2.4.2 Strategic analysis 148
13.3 LONZA GROUP LTD. 149
13.3.1 BUSINESS OVERVIEW 149
13.3.2 PRODUCTS & SERVICES 150
13.3.3 RECENT DEVELOPMENTS 150
13.3.4 MNM VIEW 151
13.3.4.1 Financial analysis 151
13.3.4.2 Strategic analysis 151
13.4 MERCK & CO., INC. 152
13.4.1 BUSINESS OVERVIEW 152
13.4.2 PRODUCT PORTFOLIO 152
13.4.3 RECENT DEVELOPMENTS 153
13.4.4 MNM VIEW 154
13.4.4.1 Financial analysis 154
13.4.4.2 Strategic analysis 154
13.5 SIGMA-ALDRICH CORPORATION 155
13.5.1 BUSINESS OVERVIEW 155
13.5.2 PRODUCT PORTFOLIO 156
13.5.3 RECENT DEVELOPMENTS 156
13.5.4 MNM VIEW 157
13.5.4.1 Financial analysis 157
13.5.4.2 Strategic analysis 157
13.6 THERMO FISHER SCIENTIFIC, INC. 158
13.6.1 BUSINESS OVERVIEW 158
13.6.2 PRODUCT PORTFOLIO 159
13.6.3 RECENT DEVELOPMENTS 159
13.6.4 MNM VIEW 160
13.6.4.1 Financial analysis 160
13.6.4.2 Strategic analysis 161
13.7 AMERICAN TYPE CULTURE COLLECTION 162
13.7.1 BUSINESS OVERVIEW 162
13.7.2 PRODUCTS & SERVICES 162
13.7.3 RECENT DEVELOPMENTS 162
13.7.4 KEY STRATEGY 162
13.8 BIOLOGICAL INDUSTRIES ISRAEL BEIT HAEMEK LTD. 163
13.8.1 BUSINESS OVERVIEW 163
13.8.2 PRODUCT PORTFOLIO 163
13.8.3 KEY STRATEGY 163
13.9 BIONIQUE TESTING LABORATORIES, INC. 164
13.9.1 BUSINESS OVERVIEW 164
13.9.2 PRODUCTS & SERVICES 164
13.9.3 KEY STRATEGY 164
13.10 INVIVOGEN 165
13.10.1 BUSINESS OVERVIEW 165
13.10.2 PRODUCT PORTFOLIO 165
13.10.3 KEY STRATEGY 165
13.11 PROMO CELL GMBH 166
13.11.1 PRODUCT PORTFOLIO 166
13.11.2 KEY STRATEGY 166
14 APPENDIX 167
14.1 INSIGHTS OF INDUSTRY EXPERTS 167
14.2 DISCUSSION GUIDE 168
14.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 170
14.4 AVAILABLE CUSTOMIZATIONS 171
14.5 RELATED REPORTS 172